SG11201510210XA - Methods for detecting prostate cancer - Google Patents

Methods for detecting prostate cancer

Info

Publication number
SG11201510210XA
SG11201510210XA SG11201510210XA SG11201510210XA SG11201510210XA SG 11201510210X A SG11201510210X A SG 11201510210XA SG 11201510210X A SG11201510210X A SG 11201510210XA SG 11201510210X A SG11201510210X A SG 11201510210XA SG 11201510210X A SG11201510210X A SG 11201510210XA
Authority
SG
Singapore
Prior art keywords
methods
prostate cancer
detecting prostate
detecting
cancer
Prior art date
Application number
SG11201510210XA
Inventor
Doug Brooks
Emma Parkinson-Lawrence
Ian Johnson
Lisa Butler
Roberto Weigert
Original Assignee
Univ South Australia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2013902141A external-priority patent/AU2013902141A0/en
Application filed by Univ South Australia filed Critical Univ South Australia
Publication of SG11201510210XA publication Critical patent/SG11201510210XA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069Reproductive system, e.g. ovaria, uterus, testes, prostate
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57434Specifically defined cancers of prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/10X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702Regulators; Modulating activity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/286Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/112Disease subtyping, staging or classification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4703Regulators; Modulating activity
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82Translation products from oncogenes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/914Hydrolases (3)
    • G01N2333/948Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433Serine endopeptidases (3.4.21)
    • G01N2333/96441Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/96455Kallikrein (3.4.21.34; 3.4.21.35)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/54Determining the risk of relapse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
SG11201510210XA 2013-06-13 2014-06-13 Methods for detecting prostate cancer SG11201510210XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2013902141A AU2013902141A0 (en) 2013-06-13 Method for detecting prostate cancer
PCT/AU2014/000612 WO2014197937A1 (en) 2013-06-13 2014-06-13 Methods for detecting prostate cancer

Publications (1)

Publication Number Publication Date
SG11201510210XA true SG11201510210XA (en) 2016-01-28

Family

ID=52021494

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201510210XA SG11201510210XA (en) 2013-06-13 2014-06-13 Methods for detecting prostate cancer

Country Status (7)

Country Link
US (3) US20160130661A1 (en)
EP (2) EP3800266A1 (en)
JP (1) JP6696896B2 (en)
CN (1) CN105658810B (en)
AU (1) AU2014280846B2 (en)
SG (1) SG11201510210XA (en)
WO (1) WO2014197937A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4036118A1 (en) 2013-08-01 2022-08-03 Five Prime Therapeutics, Inc. Afucosylated anti-fgfr2iiib antibodies
CA3004794A1 (en) 2015-11-23 2017-06-01 Five Prime Therapeutics, Inc. Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
EP3409772B1 (en) 2016-01-29 2023-06-28 National University Corporation Hokkaido University Intracellular substance transport system and use thereof
CN106282374A (en) * 2016-09-23 2017-01-04 北京致成生物医学科技有限公司 FAM13AOS is as molecular marked compound and the application thereof detecting carcinoma of prostate
CN106319070A (en) * 2016-09-28 2017-01-11 北京致成生物医学科技有限公司 Application of NEURL1B in preparation of product for diagnosing prostatic carcinoma
CN106544430A (en) * 2016-11-04 2017-03-29 叶伟亮 A kind of molecular marked compound of detection carcinoma of prostate and its application
BR112019023898A2 (en) 2017-05-16 2020-06-09 Five Prime Therapeutics Inc method for treatment of gastric cancer, use of an antibody and composition
CA3068167A1 (en) * 2017-06-23 2018-12-27 Anette Weyergang Diagnosis and treatment of cancer
CN107630091B (en) * 2017-09-20 2021-02-02 南方医科大学 Application of Myosin1b gene or protein
MX2020008702A (en) * 2018-02-22 2020-09-25 Liquid Biopsy Res Llc Methods for prostate cancer detection and treatment.
WO2020236998A2 (en) * 2019-05-21 2020-11-26 University Of Massachusetts Genetic amplified tumor homing nanoparticles and compositions and methods thereof
CN114641690A (en) * 2019-09-03 2022-06-17 远景科学私人有限公司 Methods for confirming, detecting and assessing prostate cancer progression and related treatments
JP7479504B2 (en) 2020-04-23 2024-05-08 ニュー ライフ メディシン テクノロジー カンパニー リミテッド Methods Related to Diagnosis of Prostate Cancer
CN114316018A (en) * 2021-11-26 2022-04-12 江南大学 FGF21 protein analogue and application thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US20040038240A1 (en) * 2001-07-13 2004-02-26 Akhouri Sinha Method and materials for assessing cancer aggressiveness
EP1646426A2 (en) * 2003-07-10 2006-04-19 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Appl proteins as rab5 effectors
US7838249B2 (en) * 2006-11-29 2010-11-23 The Board Of Regents Of The University Of Oklahoma Assays for rab5 activity
KR101041308B1 (en) * 2009-06-09 2011-06-14 성균관대학교산학협력단 A composition for anticancer comprising appl1 inhibitor and a method for screening regulators of interaction between appl1 and egfr
EP2776465A1 (en) * 2011-11-09 2014-09-17 Alper Biotech, Llc Monoclonal antibodies against serotransferrin antigens, and uses therefor

Also Published As

Publication number Publication date
CN105658810B (en) 2020-08-21
AU2014280846A1 (en) 2015-12-24
JP2016527483A (en) 2016-09-08
CN105658810A (en) 2016-06-08
AU2014280846B2 (en) 2020-11-05
US20160130661A1 (en) 2016-05-12
WO2014197937A1 (en) 2014-12-18
US11261496B2 (en) 2022-03-01
EP3008210A1 (en) 2016-04-20
EP3800266A1 (en) 2021-04-07
EP3008210A4 (en) 2017-05-17
US20180119229A1 (en) 2018-05-03
US20220154292A1 (en) 2022-05-19
JP6696896B2 (en) 2020-05-20
EP3008210B1 (en) 2020-10-07

Similar Documents

Publication Publication Date Title
HK1223552A1 (en) Combination therapies for cancer
HK1217218A1 (en) Biomarkers for colorectal cancer
HK1214652A1 (en) Methods and compositions for detecting pancreatic cancer
SG11201510210XA (en) Methods for detecting prostate cancer
IL246067A0 (en) Prostate cancer classification
HK1220155A1 (en) Methods for treating cancer
SG11201603050TA (en) Methods for treating cancers
LU92173B1 (en) Distance determination method
HK1213297A1 (en) Compositions and methods for detecting and determining a prognosis for prostate cancer
IL233803A0 (en) Monocyte biomarkers for cancer detection
EP2876447A4 (en) Method for detecting cancer
EP2986326A4 (en) Methods for detecting cancer metastasis
HK1220253A1 (en) Methods of detecting prostate cancer
HK1213634A1 (en) Methods of detecting cancer
GB201322800D0 (en) Prostate cancer biomarkers
HUE043162T2 (en) Method for detecting cancer
HK1216779A1 (en) Predictive biomarker for cancer therapy
IL240319A (en) Rapid detection
EP2985605A4 (en) Method for detecting colon cancer
HK1220356A1 (en) Novel therapy for prostate carcinoma
HUE048625T2 (en) Methods for treating cancer
EP3033617A4 (en) Biomarkers for prostate cancer
AU2013902141A0 (en) Method for detecting prostate cancer
GB201306394D0 (en) Cancer biomarker
GB201300369D0 (en) Biomarker panel for prostate cancer